NIAID Seeks Newly Diagnosed Type 1 Diabetes Patients for Clinical Research Studies

NIAID Seeks Newly Diagnosed Type 1 Diabetes Patients for Clinical Research Studies

The National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with the Immune Tolerance Network, is currently seeking people who recently have been diagnosed with type 1 diabetes to volunteer for clinical studies. These studies are being conducted by research teams across the United States.



► A Research Trial of Aralast in New Onset Diabetes
This study investigates the effect of intravenous Alpha-1 Antitrypsin (AAT, Aralast NP) on preserving insulin-producing beta cell function and to determine if AAT will help slow the progression of type 1 diabetes. The study seeks volunteers ages 8 to 35 who have been diagnosed with type 1 diabetes within the past 100 days.

Read more about this study and find site locations on ClinicalTrials.gov [A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I - Full Text View - ClinicalTrials.gov] and at the study Web site [Home page | Retain Dev].





► A Research Trial of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes
This study aims to determine if Thymoglobulin can halt the progression of type 1 diabetes when given within three months of diagnosis. The study seeks volunteers ages 12 to 35 who recently have been diagnosed with type 1 diabetes.

Read more about this study and find site locations on ClinicalTrials.gov [Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes - Full Text View - ClinicalTrials.gov] and at the study Web site [Home page | Retain Dev].